论文部分内容阅读
目的:探讨转化生长因子β激活酶1(TAK1)在人食管癌组织中的表达及临床意义。方法:收集2002年9月至2008年2月在我院接受手术治疗的食管癌患者80例,所有患者术后经病理结果证实,通过免疫组织化学方法检测TAK1蛋白在食管癌及其癌旁组织中的表达,并探讨TAK1表达量与临床病理特征及患者预后的相关性。结果:TAK1在食管癌组织中阳性表达率为80%,明显高于癌旁正常组织中的阳性表达率11.25%;TAK1的阳性率与食管癌患者的年龄、性别、分化程度及肿瘤大小无关(P>0.05),而与临床分期和淋巴结转移呈正相关性(P<0.05)。此外,研究还发现TAK1的表达量与患者的5年生存率呈反比,高表达TAK1的患者5年生存率显著低于低表达的患者(P=0.008 5)。结论:TAK1可能是食管癌发病机制中的重要参与者,靶向TAK1的治疗有可能改善食管癌患者的预后。
Objective: To investigate the expression and clinical significance of transforming growth factor-beta-1 (TAK1) in human esophageal carcinoma. Methods: 80 patients with esophageal cancer undergoing surgical treatment in our hospital from September 2002 to February 2008 were collected. All the patients were confirmed by pathological results postoperatively. The expression of TAK1 protein in esophageal cancer and its paracancerous tissues was detected by immunohistochemistry , And to explore the correlation between the expression of TAK1 and clinicopathological characteristics and prognosis of patients. Results: The positive expression rate of TAK1 in esophageal cancer was 80%, which was significantly higher than that in normal tissue (11.25%). The positive rate of TAK1 was not related to the age, sex, differentiation and tumor size P> 0.05), but positively correlated with clinical stage and lymph node metastasis (P <0.05). In addition, the study also found that the expression of TAK1 was inversely proportional to the 5-year survival rate of patients, and the 5-year survival rate of patients with high expression of TAK1 was significantly lower than that of patients with low expression (P = 0.008 5). Conclusion: TAK1 may be an important participant in the pathogenesis of esophageal cancer. Targeting TAK1 may improve the prognosis of esophageal cancer patients.